Superbug and viral pathogen treatment developer Recce Pharmacetical (ASX:RCE)’s unapproved drug R327 has successfully saved a patient suffering a life-threatening illness.
Despite not undertaking clinical trials, nasal treatment R327 was accessible to the individual via Category A of the Therapeutic Goods Administration special access scheme. Recce (ASX:RCE) intends to proceed with clinical trials for the product.
The news has shot Recce’s shares up 5.1 per cent to $1.03
Copyright 2021 – Finance News Network
18 Aug 2020 - Ingenia Communities Group (ASX:INA) today announced underlying profit of $59.1 million for the year ending 30 June 2020, an increase of 25 per cent on the previous financial year.
13 Apr 2021 - Payment solutions provider Zip Co (ASX:Z1P) has reported March quarter revenue of over $114 million, indicating an 80 per cent rise year on year.
30 Sep 2019 - Dairy company Fonterra’s (ASX:FSF) Australian milk production decreased 8.4 per cent in July compared to the same period last year. Production for the 12 months to July was also down 8.4 per cent on the previous 12 months. Dairy Australia is forecasting 2019/20 season production to decline by 3 per cent to 5 per cent.
24 May 2022 - Snap’s share price dived over 28% after an earnings miss, warning investors of a hiring slowdown with the Nasdaq futures falling 1.3% as investors fret about tech giant’s reliance on internet advertising. The news pulled Facebook-owner Meta Platforms and Google-owner Alphabet down 7 and almost 4% respectively.
02 Dec 2019 - The Woolworths Group (ASX:WOW) has been notified that a Canberra law firm has announced its intention to file employee class action proceedings against them in relation to payment shortfalls to salaried store team members covered by the General Retail Industry Award.
